Platelet tyrosine kinases and fibrinogen receptor activation

Mark I. Furman, Dmitriy Grigoryev, Paul F. Bray, Kirk R. Dise, Pascal Goldschmidt-Clermont

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Platelet adhesion and aggregation during hemostasis and thrombosis are usually limited to sites where the integrity of the vessel wall is disrupted. The high concentration of platelet agonists within these sites represents a putative control mechanism for targeting platelet activation. Although much has been learned about the intracellular signaling systems controlling platelet activation, our understanding of the connection between signaling molecules and platelet aggregation remains limited. Tyrosine kinases are important signaling enzymes in cells and are abundant in platelets. Previous reports indicate that binding of glycoprotein IIb-IIIa (GPIIb-IIIa) to fibrinogen can induce the tyrosine phosphorylation of specific substrates. We show that, in turn, protein tyrosine kinase activity is necessary for agonist-induced activation of GPIIb-IIIa. Genistein and the tyrphostin AG-18 are two specific tyrosine kinase inhibitors, and the former has been shown to inhibit platelet aggregation. We use genistein and AG-18 in the present study to demonstrate that aggregation inhibition is due to suppression of GPIIb- IIIa activation. In contrast, genistin, an isoflavone compound related to genistein, and acetylsalicylic acid do not affect the tyrosine kinase- signaling pathway, nor do they inhibit GPIIb-IIIa activation induced by strong agonists. On identifying prominent tyrosine kinase substrates in activated platelets, we confirm that several substrates correspond to proteins associated with the cytoskeleton: the 85-kD subunit of phosphatidylinositol 3-kinase, the SH3-containing and actin-associating p85, pp60(Src), and pp125(FAK). Our data showing that tyrosine kinase activity is required for GPIIb-IIIa activation, together with previous studies indicating that fibrinogen binding to its receptor results in tyrosine phosphorylation of platelet substrates, suggest that a dual regulatory mechanism allows for full platelet response only at sites where both pathways are activated, namely disrupted vessel walls.

Original languageEnglish
Pages (from-to)172-180
Number of pages9
JournalCirculation Research
Volume75
Issue number1
StatePublished - Jul 1 1994
Externally publishedYes

Fingerprint

Fibrinogen Receptors
Receptor Protein-Tyrosine Kinases
Protein-Tyrosine Kinases
Blood Platelets
Genistein
Platelet Aggregation
Platelet Activation
Fibrinogen
Tyrosine
Phosphorylation
Phosphatidylinositol 3-Kinase
Tyrphostins
Platelet Glycoprotein GPIIb-IIIa Complex
Isoflavones
Hemostasis
Cytoskeleton
Aspirin
Actins
Thrombosis
Enzymes

Keywords

  • cytoskeleton
  • glycoprotein IIb-IIIa
  • integrins
  • platelets
  • tyrosine kinases

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Furman, M. I., Grigoryev, D., Bray, P. F., Dise, K. R., & Goldschmidt-Clermont, P. (1994). Platelet tyrosine kinases and fibrinogen receptor activation. Circulation Research, 75(1), 172-180.

Platelet tyrosine kinases and fibrinogen receptor activation. / Furman, Mark I.; Grigoryev, Dmitriy; Bray, Paul F.; Dise, Kirk R.; Goldschmidt-Clermont, Pascal.

In: Circulation Research, Vol. 75, No. 1, 01.07.1994, p. 172-180.

Research output: Contribution to journalArticle

Furman, MI, Grigoryev, D, Bray, PF, Dise, KR & Goldschmidt-Clermont, P 1994, 'Platelet tyrosine kinases and fibrinogen receptor activation', Circulation Research, vol. 75, no. 1, pp. 172-180.
Furman MI, Grigoryev D, Bray PF, Dise KR, Goldschmidt-Clermont P. Platelet tyrosine kinases and fibrinogen receptor activation. Circulation Research. 1994 Jul 1;75(1):172-180.
Furman, Mark I. ; Grigoryev, Dmitriy ; Bray, Paul F. ; Dise, Kirk R. ; Goldschmidt-Clermont, Pascal. / Platelet tyrosine kinases and fibrinogen receptor activation. In: Circulation Research. 1994 ; Vol. 75, No. 1. pp. 172-180.
@article{3c72cec19ae94b6ba296242b79059d8b,
title = "Platelet tyrosine kinases and fibrinogen receptor activation",
abstract = "Platelet adhesion and aggregation during hemostasis and thrombosis are usually limited to sites where the integrity of the vessel wall is disrupted. The high concentration of platelet agonists within these sites represents a putative control mechanism for targeting platelet activation. Although much has been learned about the intracellular signaling systems controlling platelet activation, our understanding of the connection between signaling molecules and platelet aggregation remains limited. Tyrosine kinases are important signaling enzymes in cells and are abundant in platelets. Previous reports indicate that binding of glycoprotein IIb-IIIa (GPIIb-IIIa) to fibrinogen can induce the tyrosine phosphorylation of specific substrates. We show that, in turn, protein tyrosine kinase activity is necessary for agonist-induced activation of GPIIb-IIIa. Genistein and the tyrphostin AG-18 are two specific tyrosine kinase inhibitors, and the former has been shown to inhibit platelet aggregation. We use genistein and AG-18 in the present study to demonstrate that aggregation inhibition is due to suppression of GPIIb- IIIa activation. In contrast, genistin, an isoflavone compound related to genistein, and acetylsalicylic acid do not affect the tyrosine kinase- signaling pathway, nor do they inhibit GPIIb-IIIa activation induced by strong agonists. On identifying prominent tyrosine kinase substrates in activated platelets, we confirm that several substrates correspond to proteins associated with the cytoskeleton: the 85-kD subunit of phosphatidylinositol 3-kinase, the SH3-containing and actin-associating p85, pp60(Src), and pp125(FAK). Our data showing that tyrosine kinase activity is required for GPIIb-IIIa activation, together with previous studies indicating that fibrinogen binding to its receptor results in tyrosine phosphorylation of platelet substrates, suggest that a dual regulatory mechanism allows for full platelet response only at sites where both pathways are activated, namely disrupted vessel walls.",
keywords = "cytoskeleton, glycoprotein IIb-IIIa, integrins, platelets, tyrosine kinases",
author = "Furman, {Mark I.} and Dmitriy Grigoryev and Bray, {Paul F.} and Dise, {Kirk R.} and Pascal Goldschmidt-Clermont",
year = "1994",
month = "7",
day = "1",
language = "English",
volume = "75",
pages = "172--180",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Platelet tyrosine kinases and fibrinogen receptor activation

AU - Furman, Mark I.

AU - Grigoryev, Dmitriy

AU - Bray, Paul F.

AU - Dise, Kirk R.

AU - Goldschmidt-Clermont, Pascal

PY - 1994/7/1

Y1 - 1994/7/1

N2 - Platelet adhesion and aggregation during hemostasis and thrombosis are usually limited to sites where the integrity of the vessel wall is disrupted. The high concentration of platelet agonists within these sites represents a putative control mechanism for targeting platelet activation. Although much has been learned about the intracellular signaling systems controlling platelet activation, our understanding of the connection between signaling molecules and platelet aggregation remains limited. Tyrosine kinases are important signaling enzymes in cells and are abundant in platelets. Previous reports indicate that binding of glycoprotein IIb-IIIa (GPIIb-IIIa) to fibrinogen can induce the tyrosine phosphorylation of specific substrates. We show that, in turn, protein tyrosine kinase activity is necessary for agonist-induced activation of GPIIb-IIIa. Genistein and the tyrphostin AG-18 are two specific tyrosine kinase inhibitors, and the former has been shown to inhibit platelet aggregation. We use genistein and AG-18 in the present study to demonstrate that aggregation inhibition is due to suppression of GPIIb- IIIa activation. In contrast, genistin, an isoflavone compound related to genistein, and acetylsalicylic acid do not affect the tyrosine kinase- signaling pathway, nor do they inhibit GPIIb-IIIa activation induced by strong agonists. On identifying prominent tyrosine kinase substrates in activated platelets, we confirm that several substrates correspond to proteins associated with the cytoskeleton: the 85-kD subunit of phosphatidylinositol 3-kinase, the SH3-containing and actin-associating p85, pp60(Src), and pp125(FAK). Our data showing that tyrosine kinase activity is required for GPIIb-IIIa activation, together with previous studies indicating that fibrinogen binding to its receptor results in tyrosine phosphorylation of platelet substrates, suggest that a dual regulatory mechanism allows for full platelet response only at sites where both pathways are activated, namely disrupted vessel walls.

AB - Platelet adhesion and aggregation during hemostasis and thrombosis are usually limited to sites where the integrity of the vessel wall is disrupted. The high concentration of platelet agonists within these sites represents a putative control mechanism for targeting platelet activation. Although much has been learned about the intracellular signaling systems controlling platelet activation, our understanding of the connection between signaling molecules and platelet aggregation remains limited. Tyrosine kinases are important signaling enzymes in cells and are abundant in platelets. Previous reports indicate that binding of glycoprotein IIb-IIIa (GPIIb-IIIa) to fibrinogen can induce the tyrosine phosphorylation of specific substrates. We show that, in turn, protein tyrosine kinase activity is necessary for agonist-induced activation of GPIIb-IIIa. Genistein and the tyrphostin AG-18 are two specific tyrosine kinase inhibitors, and the former has been shown to inhibit platelet aggregation. We use genistein and AG-18 in the present study to demonstrate that aggregation inhibition is due to suppression of GPIIb- IIIa activation. In contrast, genistin, an isoflavone compound related to genistein, and acetylsalicylic acid do not affect the tyrosine kinase- signaling pathway, nor do they inhibit GPIIb-IIIa activation induced by strong agonists. On identifying prominent tyrosine kinase substrates in activated platelets, we confirm that several substrates correspond to proteins associated with the cytoskeleton: the 85-kD subunit of phosphatidylinositol 3-kinase, the SH3-containing and actin-associating p85, pp60(Src), and pp125(FAK). Our data showing that tyrosine kinase activity is required for GPIIb-IIIa activation, together with previous studies indicating that fibrinogen binding to its receptor results in tyrosine phosphorylation of platelet substrates, suggest that a dual regulatory mechanism allows for full platelet response only at sites where both pathways are activated, namely disrupted vessel walls.

KW - cytoskeleton

KW - glycoprotein IIb-IIIa

KW - integrins

KW - platelets

KW - tyrosine kinases

UR - http://www.scopus.com/inward/record.url?scp=0028284676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028284676&partnerID=8YFLogxK

M3 - Article

VL - 75

SP - 172

EP - 180

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 1

ER -